Scotiabank maintains Amgen at Sector Outperform, raises price target to $530 from $500

What happened

Scotiabank kept its Sector Outperform rating on Amgen and raised its price target to $530 from $500, a 6.0% increase. The new target implies 10.8% upside from Amgen’s Nov. 4 closing price of $478.48.

Confirmed

Global impact / market context

A higher target signals that Scotiabank sees more potential value in Amgen shares, which may support investor interest. The rating and target are analyst opinions, however, not company guidance or a promise that the share price will reach $530.

Analyst inference

Recent analyst targets span $410 to $536 across five notes published over the past 30 days, showing differing views on Amgen’s value. Scotiabank’s $530 target sits near the top of that range, alongside another target near that level.

Confirmed

What to watch

1. Compare upcoming analyst targets with Scotiabank’s $530 view and the recent $410–$536 range to see whether opinions on Amgen are converging or widening. Analyst inference
2. Watch whether Amgen’s share price moves toward or away from the target’s implied 10.8% upside from the Nov. 4 close of $478.48. Analyst inference
3. The article reports no change to Scotiabank’s Sector Outperform rating; note whether future analyst updates retain that rating or revise it. Confirmed

Evidence

• Original source link unavailable